NasdaqGM - Nasdaq Real Time Price USD

Invivyd, Inc. (IVVD)

2.1500

+0.0800

(+3.86%)

At close: April 26 at 4:00 PM EDT

2.2100

+0.06

(+2.79%)

After hours: April 26 at 5:25 PM EDT

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administrationReimbursement through Medicare/Medicaid represents approximately 50% of covered lives in target population WALTHAM, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the U.S. Centers for Medica

GlobeNewswire 12 days ago
Invivyd Announces CEO Transition

Jeremy Gowler appointed Interim CEOWALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effective immediately, while the Board institutes a search for a permanent CEO. Mr. Gowler succeeds Dave Hering. “The Invivyd Board of Directors is posit

GlobeNewswire 15 days ago
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net product revenue and continued optimization of operational expenses, company expects to end 2024 with at least $55 million in cash and cash equivalentsConference call today at 5 pm ET to discuss PEMGARDA launch progress WALTHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a b

GlobeNewswire 23 days ago
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise PEMGARDA product availability in the U.S. anticipated imminentlyPEMGARDA is the first authorized mAb from Invivyd’s INVYMAB™ platform approach designed to address the challenge of rapid viral evolutionLeveraged INVYMAB platform approach to design VYD2311, the company’s nex

GlobeNewswire 30 days ago
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development workToday’s update on Day 67 and Day 90 event rates is the first of two planned public updates on symptomatic COVID-19 events in CANOPY; Invivyd plans to analyze all future events at Day 180Further defining the relationship between serum virus neutralizing antibody titers and clinical protection that pro

GlobeNewswire last month
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Figure 1. Calculated sVNA titers against JN.1 based on observed pharmacokinetic concentration by timepoints (Cohort A) Figure 1 PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clinical trial along with ongoing in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1PEMGARDA is

GlobeNewswire last month
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

WALTHAM, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, Chief Executive Officer of Invivyd, is scheduled to present in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 1:00 p.m. ET in New York, NY. In addition to the fireside chat, the management team will host i

GlobeNewswire 2 months ago
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variantsVYD222 demonstrates continued in vitro neutralization activity against major SARS-CoV-2 variants, including JN.1, currently the fastest growing variant in the U.S. Company continues preparations for potential commercial launch if EUA is granted WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Na

GlobeNewswire 3 months ago
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participantsData supportive of an immunobridging approach to the EVADE study of adintrevimab Overall favorable safety and tolerability profile of VYD222 including no study drug-related serious adverse events (SAEs) to dateVYD222 demonstrates continued in-vitro neutralization activity against major SARS-CoV-2 variants, including against HV.1, the currently dominant variant in the U.S. WALTHAM, Mass., Dec. 18,

GlobeNewswire 4 months ago
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024Company aims to submit an application for Emergency Use Authorization (EUA) in the U.S. as soon as practicableCompany continues to advance INVYMABTM, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threatsCash, cash equivalent

GlobeNewswire 5 months ago
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the

GlobeNewswire 5 months ago
Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences: Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceFireside Chat Date: Tuesday, November 7, 2023Fireside Chat Time: 3:50 PM ETLocation: New York, NY Evercore ISI 6th Annual HealthCONx ConferenceFire

GlobeNewswire 5 months ago
Invivyd Appoints William Duke as Chief Financial Officer

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of William Duke as Chief Financial Officer. Mr. Duke will lead Invivyd’s financial strategy to support the company’s continued growth. Mr. Duke has more than 25 years of finance, accounting, and operations experience, including over a decade of senior leadership ex

GlobeNewswire 7 months ago
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels testedPlans to pursue rapid initiation of a 750-participant pivotal clinical trial of VYD222 (CANOPY) that will utilize Day 28 serum neutralizing titers from a subset of the population as part of a potential EUA submission for the prevention of symptomatic COVID-19The company expects to have initial primary endpoint data from CANOPY by appr

GlobeNewswire 8 months ago
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the quest

GlobeNewswire 8 months ago
Invivyd Announces Appointment of Sara Cotter to Board Of Directors

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development. “Ms. Cotter’s comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital ma

GlobeNewswire 8 months ago
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Continued favorable safety and tolerability profile for all dose levels testedSerum samples from all dose levels tested showed robust neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globallyOngoing analysis of serum neutralizing activity and pharmacokinetic data expected to support rapid anticipated transition to pivotal clinical trial WALTHAM, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceu

GlobeNewswire 9 months ago
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype antibodyVYD222 and potential future Invivyd mAbs are planned to leverage this EUA pathway using consistent manufacturing platform and limited structural changes from proprietary prototype antibody ADG20 (adintrevimab)Company confirms plans to pursue rapid initiation of a VYD222 pivotal clinical trial usin

GlobeNewswire 9 months ago
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to date As predicted by pre-clinical in vitro testing, early serum samples from the first, lowest dose cohort showed strong neutralization activity against Omicron XBB.1.5, one of the dominant SARS-CoV-2 variants circulating globally Initial Phase 1 data help support anticipated rapid transition to a pivotal clinical trial WALTHAM, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: I

GlobeNewswire 10 months ago
Invivyd to Participate at the Jefferies Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that David Hering, chief executive officer of Invivyd, is scheduled to present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 11:30 a.m. ET in New York, NY. In addition to the presentation, the management team will host investor meetings at the conference. Invest

GlobeNewswire 10 months ago

Performance Overview

Return	IVVD	S&P 500
YTD	-45.43%	+6.92%
1-Year	+93.69%	+25.26%
3-Year	--	+14.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Invivyd, Inc. (IVVD)

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Invivyd Announces CEO Transition

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents

Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Appoints William Duke as Chief Financial Officer

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Invivyd to Participate at the Jefferies Healthcare Conference

Performance Overview